Literature DB >> 17934088

Updated consensus statement on biological agents for the treatment of rheumatic diseases, 2007.

D E Furst1, F C Breedveld, J R Kalden, J S Smolen, G R Burmester, J Sieper, P Emery, E C Keystone, M H Schiff, P Mease, P L C M van Riel, R Fleischmann, M H Weisman, M E Weinblatt.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2007        PMID： 17934088      PMCID： PMC2095281          DOI： 10.1136/ard.2007.081430

Source DB:  PubMed          Journal:  Ann Rheum Dis        ISSN： 0003-4967            Impact factor:   19.103


× No keyword cloud information.
  417 in total

1.  Treatment of rheumatic inflammatory disease in 25 patients with secondary amyloidosis using tumor necrosis factor alpha antagonists.

Authors:  Antonio Fernández-Nebro; Eva Tomero; Vera Ortiz-Santamaría; María Carmen Castro; Alejandro Olivé; Manuel de Haro; Rosa García Portales; Rosa García-Vicuña; María Victoria González-Mari; Armando Laffón; Rosario García-Vicuña
Journal:  Am J Med       Date:  2005-05       Impact factor: 4.965

2.  Successful treatment of refractory Schnitzler syndrome with anakinra: comment on the article by Hawkins et al.

Authors:  Victor Manuel Martinez-Taboada; Ana Fontalba; Ricardo Blanco; Jose Luis Fernández-Luna
Journal:  Arthritis Rheum       Date:  2005-07

3.  Adalimumab: a new modality for Behçet's disease?

Authors:  J A M van Laar; T Missotten; P L A van Daele; A Jamnitski; G S Baarsma; P M van Hagen
Journal:  Ann Rheum Dis       Date:  2006-11-23       Impact factor: 19.103

4.  Adalimumab treatment for pyoderma gangrenosum.

Authors:  Michael P Heffernan; Milan J Anadkat; David I Smith
Journal:  Arch Dermatol       Date:  2007-03

5.  Treatment of recurrent Sweet's syndrome with coexisting rheumatoid arthritis with the tumor necrosis factor antagonist etanercept.

Authors:  Paul S Yamauchi; Logan Turner; Nicholas J Lowe; Vivian Gindi; J Mark Jackson
Journal:  J Am Acad Dermatol       Date:  2006-03       Impact factor: 11.527

6.  The comparative effectiveness of anti-TNF therapy and methotrexate in patients with psoriatic arthritis: 6 month results from a longitudinal, observational, multicentre study.

Authors:  M S Heiberg; C Kaufmann; E Rødevand; K Mikkelsen; W Koldingsnes; P Mowinckel; T K Kvien
Journal:  Ann Rheum Dis       Date:  2007-01-09       Impact factor: 19.103

7.  Anakinra prevents symptoms of familial cold autoinflammatory syndrome and Raynaud's disease.

Authors:  Samy K Metyas; Hal M Hoffman
Journal:  J Rheumatol       Date:  2006-09-15       Impact factor: 4.666

8.  Induction of autoantibodies in refractory rheumatoid arthritis treated by infliximab.

Authors:  Y Allanore; J Sellam; F Batteux; C Job Deslandre; B Weill; A Kahan
Journal:  Clin Exp Rheumatol       Date:  2004 Nov-Dec       Impact factor: 4.473

9.  Demyelination occurring during anti-tumor necrosis factor alpha therapy for inflammatory arthritides.

Authors:  N Mohan; E T Edwards; T R Cupps; P J Oliverio; G Sandberg; H Crayton; J R Richert; J N Siegel
Journal:  Arthritis Rheum       Date:  2001-12

10.  Combined therapy with rituximab plus cyclophosphamide/doxorubicin/vincristine/prednisone (CHOP) for Sjögren's syndrome-associated B-cell aggressive non-Hodgkin's lymphomas.

Authors:  M Voulgarelis; S Giannouli; D Anagnostou; A G Tzioufas
Journal:  Rheumatology (Oxford)       Date:  2004-06-08       Impact factor: 7.580
View more
  46 in total

1.  An open-label pilot study of the efficacy and safety of anakinra in patients with psoriatic arthritis refractory to or intolerant of methotrexate (MTX).

Authors:  Norma Jung; Matthias Hellmann; Reimund Hoheisel; Clara Lehmann; Ingo Haase; Andreas Perniok; Michael Hallek; Andrea Rubbert
Journal:  Clin Rheumatol       Date:  2010-06-09       Impact factor: 2.980

Review 2.  Advances in the medical treatment of rheumatoid arthritis.

Authors:  J Michelle Kahlenberg; David A Fox
Journal:  Hand Clin       Date:  2011-02       Impact factor: 1.907

Review 3.  Does rituximab increase the incidence of infectious complications? A narrative review.

Authors:  Theodoros Kelesidis; George Daikos; Dimitrios Boumpas; Sotirios Tsiodras
Journal:  Int J Infect Dis       Date:  2010-11-11       Impact factor: 3.623

4.  Infliximab for reactive arthritis secondary to Chlamydia trachomatis infection.

Authors:  Marcelo Derbli Schafranski
Journal:  Rheumatol Int       Date:  2009-05-23       Impact factor: 2.631

5.  [Recommedations for the use of abatacept in patients with rheumatoid arthritis].

Authors:  K Krüger; M Gaubitz
Journal:  Z Rheumatol       Date:  2008-11       Impact factor: 1.372

6.  [Rheumatoid arthritis today].

Authors:  N Leuchten; M Aringer
Journal:  Internist (Berl)       Date:  2008-12       Impact factor: 0.743

Review 7.  Biologic treatments for systemic rheumatic diseases.

Authors:  Y Shirota; G G Illei; N P Nikolov
Journal:  Oral Dis       Date:  2008-02-14       Impact factor: 3.511

8.  Digital vasculitis: a late complication of anti-tumour necrosis factor alpha therapy.

Authors:  Pamela Mangat; Samuel Whittle; Les Cleland; Vidya Limaye
Journal:  Clin Rheumatol       Date:  2008-09-27       Impact factor: 2.980

9.  Determining a low disease activity threshold for decision to maintain disease-modifying antirheumatic drug treatment unchanged in rheumatoid arthritis patients.

Authors:  Michel de Bandt; Bruno Fautrel; Jean Francis Maillefert; Jean Marie Berthelot; Bernard Combe; René-Marc Flipo; Frédéric Lioté; Olivier Meyer; Alain Saraux; Daniel Wendling; Xavier Le Loët; Francis Guillemin
Journal:  Arthritis Res Ther       Date:  2009-10-23       Impact factor: 5.156

10.  Update on the use of etanercept across a spectrum of rheumatoid disorders.

Authors:  Bernard Combe
Journal:  Biologics       Date:  2008-06
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.